BioLineRx's GLIX1 Shows Strong Synergy with PARP Inhibitors in Ovarian Cancer, Plans Trial Expansion
BLRX sits 50% above its 52-week low of $2.15 on light trading volume (0.3× avg).
Summary
BioLineRx announced highly encouraging new preclinical data for its lead asset, GLIX1, demonstrating strong synergistic effects with PARP inhibitors in a patient-derived ovarian cancer xenograft model. The combination showed substantially better efficacy than individual drugs and comparable efficacy to cisplatin chemotherapy. This builds on earlier preclinical findings regarding GLIX1's synergistic activity. Based on these results, BioLineRx plans to add an ovarian cancer arm to the expansion part of its ongoing Phase 1/2a study, which could significantly broaden GLIX1's market potential. Updates to the Phase 1/2a trial are anticipated during H2 2026.
At the time of this announcement, BLRX was trading at $3.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.9M. The 52-week trading range was $2.15 to $5.06. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.